Ad Header



The Pulse of the Pharmaceutical Industry

Roche says Hemlibra effective in pivotal study

Written by: | | Dated: Monday, December 3rd, 2018


ZURICH (Reuters) – Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of hemophilia, the Swiss drugmaker said on Monday.

Nearly 77 percent of children receiving Hemlibra once weekly experienced no treated bleeds, while Hemlibra once weekly reduced treated bleeds by 99 percent compared to prior bypassing agents, it said in a statement. Hemlibra every two weeks and every four weeks also showed clinically meaningful control of bleeding, it added.

Data from the phase III HAVEN 2 study evaluating Hemlibra in children younger than 12 with hemophilia A with factor VIII inhibitors were presented at the 60th American Society of Hematology annual meeting.


Reporting by Michael Shields; Editing by Adrian Croft


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom